Europe, Russia and Australia approved a patent for Israeli biotech Kamada’s nebulizer that delivers its Alpha1-Proteinase Inhibitor–Human (AAT) treatment for lung disease. AAT also treats Type 1 diabetes and immune system diseases. Its USA brand name is Glassia.

http://www.marketwatch.com/story/kamada-granted-key-new-patent-for-inhaled-aat-and-eflow-nebulizer-system-in-israel-2015-07-01

http://www.kamada.com/press_item.php?ID=141